Loading...
The original phase III trial for treatment of newly diagnosed glioblastoma limited enrollment to patients ≤70 years old, which left open the question of whether combined radiation therapy (RT) with temozolomide (TMZ) was beneficial for patients older than 70. In addition, post hoc subgroup analyses showed that the benefit from adding TMZ lessened with increasing age, leading some to question the value of chemoradiation over single-modality treatment in patients aged 65 to 70.
Now, researchers have conducted a retrospective analysis of treatments for 16,717 patients with glioblastoma aged ≥65 with data in the National Cancer Database, during the period after TMZ came into widespread use. Therapeutic RT was considered to be 10 to 35 fractions,…